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Abstract Objectives: Drug-induced liver injury (DILI) is
a common concern. However, data on DILI epidemi-
ology in inpatients are sparse.
Methods: To investigate the incidence of DILI, we
screened all patients in the pharmacoepidemiological
inpatient database according to the CIOMS (Council for
International Organisation of Medical Science) criteria,
which consist of the evaluation of some clinical chem-
istry laboratory liver parameters (CIOMS laboratory
criteria) and the exclusion of any disease-related causes
for the liver injury. Thus, only cases with probable or
certain causality according to the World Health Orga-
nization criteria were included.
Results: Among a total of 6383 patients, liver parameters
were determined in 4610, and 489 among them fulﬁlled
the CIOMS laboratory criteria. However, 401 patients
had to be excluded because of disease-related liver injury
and, thus, the study cohort consisted of 4209 patients at
risk for DILI. Among a total of 88 DILI cases, 31 had
no documented normal baseline liver parameters and,
thus, represented prevalent cases. The remaining 57
represented incident DILI cases. Thus, the incidence of
DILI was 1.4% (95% CI 1.0, 1.7). The drug classes most
frequently causing DILI were heparins, antibacterials,
tuberculostatics and antineoplastic agents. Among
those, antineoplastic agents and tuberculostatics showed
the highest incidence. Liver injury was not mentioned
among the diagnoses or in the physician’s discharge
letter in about 52–68% of all cases.
Conclusion: Approximately 1 in 100 patients develops
DILI during hospitalisation in a department of medi-
cine. Incidences of DILI were highest for antineoplastic
agents and tuberculostatics. DILI is frequently missed
and, therefore, DILI detection by diagnoses will result in
misleadingly low incidence rates.
Introduction
Drug-induced liver injury (DILI) represents a frequently
observed adverse drug reaction. Almost all drugs can
cause liver enzyme elevations and DILI. However, the
majority of drugs exhibit low incidences of hepatic ad-
verse reactions. Therefore, DILI is mostly identiﬁed only
after broad clinical drug application (phase IV). Well-
established causes of DILI include non-steroidal anti-
inﬂammatory drugs (NSAIDs), antibiotics, antiepilep-
tics, statins, tuberculostatics and herbal medicines [1, 2].
The incidence of DILI has so far been investigated
mainly in large outpatient cohorts by screening for
hospital admissions due to acute liver injury [3]. In a
recent, prospective, population-based cohort study in
France, the global outpatient DILI incidence amounted
to 14 cases per 100,000 inhabitants (i.e. 0.014%) [4]. For
inpatients, however, data on incidences and causes of
DILI are scarce. The largest published study detected 13
DILI cases by evaluating 147 consecutive inpatients with
liver enzyme elevations among 1964 admissions [5].
Thus, DILI was observed overall in 0.7% of inpatients
with 0.2% admitted to hospital because of DILI [5].
Hence, DILI incidence in the latter inpatient study
amounted to 0.5%, suggesting that DILI might develop
more frequently in inpatients than in those in ambula-
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tory care. In this study, we used a pharmacoepidemio-
logical database on medical inpatients [6] to determine
DILI prevalence at admission and overall, as well as
drug-speciﬁc DILI incidences in medical inpatients.
Furthermore, we also evaluated the type, the outcome
and the fraction diagnosed correctly by the physician in
charge of the observed DILI cases.
Patients and methods
Patients
The SAS/CHDM (Stiftung fu¨r Arzneimittelsicherheit/
Comprehensive Hospital Drug Monitoring) project
maintains a pharmacoepidemiological database for the
purpose of studying adverse drug events in a cohort of
medical inpatients [6]. The cohort includes all patients
admitted to two to three representative wards at the
Departments of Medicine of the University Hospital
Zu¨rich and the Kantonsspital (State Hospital) St. Gal-
len. While the former represents mainly a tertiary
referral centre and serves as primary hospital only for
some quarters of the city; the latter is a primary city
hospital and a secondary referral centre for the north-
eastern region of Switzerland. In the University Hospital
Zurich, the monitored wards belong to the Department
of Internal Medicine, where admissions are placed based
on available beds independent of the suspected diagno-
ses, whereas in the State Hospital of St. Gallen the
monitored units belong to one of three Divisions of
Department of Internal Medicine, preferentially focus-
sing on infectious, endocrine and pulmonary diseases.
The exact data recording procedure within the SAS/
CHDM project has been described previously [6]. The
database contains structured information on patient
characteristics, patient history, clinical events, labora-
tory results, diagnoses according to International Clas-
siﬁcation of Disease 10 (ICD10) and detailed drug
utilisation prior and during cohort stay. All patients
recorded between 1/1996 and 12/2000 were included for
analysis.
Case identiﬁcation
Patients with DILI were identiﬁed according to the CI-
OMS (Council for International Organizations of
Medical Science) criteria, which are based on selected
laboratory liver parameters (CIOMS laboratory criteria)
and the exclusion of any disease-related causes of liver
injury [7]. The CIOMS laboratory criteria require at
least two determinations of alanine aminotransferase
(ALT) plasma concentrations above 2 N (N stands for
upper limit of normal range) (criterion I), conjugated
bilirubin above 2 N (criterion II) or combined increases
of aspartate amino-transferase (AST), alkaline phos-
phatase (AP) and total bilirubin (tBili) with one value
above 2 N (criterion III). All patients meeting the
CIOMS laboratory criteria were assessed by at least two
of the authors, one of them an experienced clinical
pharmacologist. The liver injury was classiﬁed as disease
related if (a) a primary liver disease was diagnosed, (b) a
recent history of alcohol or cocaine abuse was reported
or (c) the time course of the liver parameter elevation
was suggestive of an association with an underlying
disease such as infectious disease, congestive heart fail-
ure, cardiac arrest, acute transitory severe hypotension
or autoimmune disease. The assessments were based on
all information available in the patients’ charts; how-
ever, no additional tests could be obtained only for the
purpose of this study. So, for example, an ultrasound
examination of the liver was available in 51% (no dis-
ease-related causes detected), serologies for hepatitis B/
C in 16% (all negative), autoantibodies in 7% (all neg-
ative) and serum ferritin 6% (all negative) of DILI cases.
Since all cases with possible disease-related liver injury
were excluded, the ﬁnal analysis included only DILI
cases with probable or certain overall causality
according to the World Health Organization (WHO)
deﬁnitions for adverse drug reactions (see http://
www.who-umc.org/defs.html#caar).
Type of DILI
The type of liver injury was determined based on the ﬁrst
laboratory determination corresponding to liver injury
according to the CIOMS criteria [7]. Cases with isolated
ALT elevation above 2 N or ALT/AP ratio above 5
(with ALT and AP expressed as multiples of the upper
normal limit) were classiﬁed as hepatocellular, cases with
ALT/AP ratio below 2 as cholestatic and cases with an
ALT/AP ratio between 2 and 5 as mixed liver injuries.
Causality assessment for individual drugs
All medication records were examined, and the time
course of the liver parameters was compared with types
and dosage histories for all drugs administered before or
at the time of liver injury. The type of liver injury and
the clinical presentation of the identiﬁed cases were
compared with those described for the suspected drugs
in the literature [8–10]. The causality between drugs and
liver injury was determined according to the WHO
deﬁnitions for adverse drug reactions (see http://
www.who-umc.org/defs.html#caar): If only one drug
could be identiﬁed as causative for the DILI, the cau-
sality for this drug was classiﬁed as probable. If a re-
challenge was positive, the causality for the corre-
sponding drug was labelled certain. If more than one
drug could have caused the DILI, the causality for all
suspected drugs was labelled as possible. Drugs were
sorted and grouped according to the ATC classiﬁcation
(http://www.whocc.no/atcddd/, last update 2004). Fur-
thermore, cases with a documented decline of all liver
parameters below 2 N (see deﬁnitions above) were
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classiﬁed as recovery, whereas cases with documented
decline but with liver parameters remaining above 2 N
were labelled as improvement. The label transient was
used for cases in which the parameters recovered or
improved despite continuation of the causative drug.
Cases were labelled as censored if the patient left the
cohort while with stable elevated or increasing liver
parameters.
Validation of the physicians’ assessments
Finally, we checked for each case whether the treating
physicians mentioned a diagnosis of or any term related
to DILI somewhere in the discharge letters. For cases
where DILI was mentioned, we determined in addition
which drug(s) was(were) implicated in these documents
and made a comparison with the cause(s) identiﬁed by
our analysis.
Epidemiological and statistical evaluation
All cases with DILI at cohort entry or with no docu-
mented normal baseline values prior to DILI develop-
ment were considered as prevalent cases. In contrast,
incident cases required at least one normal liver
parameter value prior to DILI development during co-
hort stay. For statistical analysis, the denominator in-
cluded all patients with liver parameter determinations
during cohort stay and without disease-related liver in-
jury. Exact 95% conﬁdence intervals (95% CI) for
incidence and prevalence rates were calculated using the
binomial distribution [11]. For patient characteristics
and exposure times, median and the ﬁrst (Q1) and third
quartiles (Q3) are reported.
Results
Study cohort and identiﬁcation of DILI cases
Between January 1996 and December 2000, data from
6383 individual patients were recorded in the SAS/
CHDM database, where 42% of patients were female
and 58% male. The median (Q1, Q3) age was 61 (46, 74)
years. Discharge diagnoses most frequently concerned
the cardiovascular system (65%), the respiratory system
(30%), neoplasias (23%) and/or infectious diseases
(21%). The most frequently used drugs were acetami-
nophen, furosemide, dalteparin and acetylsalicylic acid.
The most frequently used antibiotics were amoxicillin/
clavulanic acid, co-trimoxazole and ciproﬂoxacin. The
median (Q1, Q3) duration of cohort stay was 8 (5, 15)
days.
Liver parameters, i.e. liver enzymes and/or bilirubin
in plasma, were determined in 4610 (72%) of the 6383
patients (Table 1). Among them, 489 patients (i.e. 11%
of those with liver parameter determinations) fulﬁlled
the CIOMS laboratory criteria and 401 patients (i.e.
82% of patients fulﬁlling the CIOMS laboratory criteria)
suﬀered from disease-related liver injury caused by cir-
rhosis (64), hepatic tumours (33), acute hepatotropic
viral hepatitis (29), chronic hepatitis B or C (12), alcohol
or cocaine abuse (45), decompensated congestive heart
failure or transitory severe hypotension (70 patients),
acute infections (64), extrahepatic cholestasis (57),
autoimmune disease (3) or other causes (24). The latter
patients were excluded from the analysis, since the
underlying primary liver disease or the disease-related
secondary liver damage precluded the adequate detec-
tion of DILI. Thus, the study cohort of patients at risk
for DILI comprises the 4209 patients with liver param-
eter determination in whom DILI detection was not
precluded by a DILI.
Among the 4209 patients at risk, 88 (2.1%) patients
had DILI (Table 1). The diagnosis of DILI was based
on an ALT increase above 2 N (criterion I) in 72 pa-
tients, a combined increase of AST, AP and total bili-
rubin with one value above 2 N (criterion III) in three
patients and both criteria I and III in 13 patients. Cri-
terion II did not contribute to any case identiﬁcation.
Among the 88 DILI patients, 31 were classiﬁed as
prevalent cases and 57 as incident cases (Table 1).
Table 1 Drug-induced liver injury (DILI) in medical inpatients
Identiﬁcation of patients with DILI in the SAS/CHDM database
Total number of
patients screened
6383
Patients with liver
parameter determinations
4610
Patients not fulﬁlling
CIOMS laboratory criteriaa
4121
Patients fulﬁlling
CIOMS laboratory criteria
489
Patients with disease-related
liver injury
401
Patients with DILI 88
DILI prevalence at admission and DILI incidence
during hospitalisation
Patients at risk for DILIb 4209 100%
Patients with DILI 88 2.1 (1.6, 2.6)%
Prevalent casesc 31 0.7 (0.4, 1.0)%
Incident casesd 57 1.4 (1.0, 1.8)%
Hepatocellular 39 0.9 (0.6, 1.3)%
Cholestatic 14 0.3 (0.1, 0.6)%
Mixed 4 0.1 (0.0, 0.2)%
a CIOMS laboratory criteria for liver injury: ALT >2·upper limit
of normal range (N) (criterion I), conjugated bilirubin >2 N (cri-
terion II) or aspartate aminotransferase, alkaline phosphatase and
total bilirubin >N provided one of them >2 N (criterion III)
b The study cohort of patients at risk for DILI comprises only
patients with liver parameter determinations in whom DILI
detection was not precluded by primary or secondary disease re-
lated liver injury
c Liver injury already present at admission or no documented
normal baseline values during cohort stay prior to the development
of DILI
d Liver injury developed during hospitalisation, i.e. documented
normal baseline values observed during cohort stay prior to the
development of DILI
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Potential risk factors predisposing to DILI
In order to identify potential risk factors predisposing to
DILI, patient characteristics of the prevalent and inci-
dent DILI cases were compared with the study cohort
(Table 2). The percentage of female patients was com-
parable among cases and the study cohort. Also, the
body mass index for the prevalent and the incident DILI
cases was comparable with or slightly lower than the
study cohort. Except for slightly younger prevalent
cases, there were also no signiﬁcant age or comorbidity-
index diﬀerences observed. Furthermore, the median
number of diﬀerent drugs per day was comparable be-
tween prevalent (6) and incident (6) DILI cases and the
study cohort (5). Thus, neither sex, age, polymorbidity
nor polypharmacy could be identiﬁed as risk factors
predisposing to DILI.
Prevalence and types of DILI at admission
Among the 31 prevalent DILI cases (Table 1), 26 (84%)
patients fulﬁlled the CIOMS criteria already at admis-
sion, thus representing reliable prevalent cases. Five
(16%) additional patients had no documented normal
liver parameters during cohort stay prior to DILI
development and, therefore, were also classiﬁed as pre-
valent cases. However, this classiﬁcation remains some-
what tentative, since the latter ﬁve patients might
possibly correspond to incident cases. Nevertheless,
based on the overall cohort of 4209 medical inpatients
with liver parameter determinations and the 31 prevalent
DILI cases, the overall DILI prevalence at admission
amounted to approximately 0.7% (0.4, 1.0) (Table 1).
The overall causality of DILI was probable for all 31
cases. In 29 cases, a single drug was identiﬁed as DILI
cause and, thus, the causality for the respective drug was
also classiﬁed as probable. In the other two cases, two
drugs could have been causative for DILI and therefore
the causality for the respective drugs were classiﬁed as
possible and the DILI counted for each of the two drugs.
Only four patients were admitted to the hospital because
of DILI. The causative drugs were amoxicillin/clavul-
anic acid, isoniazid, sulfadiazine and Chinese herbs. In
the remaining 27 prevalent cases, hospital admission was
unrelated to DILI.
The distribution of the prevalent cases to drug classes
contributing two or more cases and to types of DILI is
given in Fig. 1. Hepatocellular DILI was most fre-
quently observed with heparins (7 cases), NSAIDS (5),
anticancer agents (4), statins (2) and tuberculostastics
(2). The latter also contributed to cholestatic DILI, to-
gether with antibacterials, antimycotics and anticancer
drugs. The ﬁve NSAID-induced DILI cases were caused
by diclofenac (2), ibuprofen, ﬂurbiprofen and nimesu-
lide. DILI was caused just once by ciclosporin, furose-
mide, gestrinone and Chinese herbs.
Incidence and types of DILI during cohort stay
Based on the 57 incident cases and the 4209 inpatients at
risk, the overall DILI incidence amounted to 1.4%, with
a 95% CI of (1.0, 1.8) (Table 1). If instead all patients
including those without liver parameter determination
were included in the denominator (n=6383), a slightly
lower incidence estimate of 1.0% (0.7, 1.2) would have
been obtained. Hence, the real DILI incidence in our
patient cohort must probably lie somewhere between
0.7% and 1.8%. According to the CIOMS criteria, liver
injury was hepatocellular in 39 (0.9%), cholestatic in 14
(0.3%) and mixed in 4 (0.1%) patients.
The overall causality of DILI was certain in 2 and
probable in 55 incident cases. In 44 cases with probable
causality, a single drug could be identiﬁed as the cause of
DILI and thus the causality for the respective drug was
also classiﬁed as probable. In the remaining 11 probable
Table 2 Comparison of potential risk factors between drug-in-
duced liver injury (DILI) cases and the study cohort
n DILI cases Study cohort
Prevalent Incident
31 (100%) 57 (100%) 4209 (100%)
Female 14 (45%) 21 (37%) 1773 (42%)
Agea 44 (35, 62) 56 (36, 70) 61 (46, 74)
Body mass
index (kg/m2)a
24.5 (22.0, 27.6) 23.8 (20.8, 27.6) 24.5 (21.4, 27.7)
Comorbidity
indexa
1 (0, 3.5) 2 (0, 3) 1 (0, 3)
Number of
diﬀerent
drugs per daya
6 (3, 8) 6 (4, 8) 5 (3, 7)
a a given as median (Q1, Q3)
Fig. 1 Causative drugs in 31 prevalent cases of drug-induced liver
injury (DILI) according to drug class and type of liver injury. The
drugs most commonly causing DILI were heparins (ATC classiﬁ-
cation: B01AB) followed by anticancer agents (L01), non-steroidal
anti-inﬂammatory drugs (NSAIDs, N02B), antibacterials for
systemic use (J01), tuberculostatics (J04), antimycotics for systemic
use (J02) and statins (C10AA)
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cases, 2 drugs could have been causative for DILI and,
therefore, the causality for the respective drugs were
classiﬁed as possible and the DILI counted for each of
the two drugs.
The distribution of the incident cases to drug classes
contributing two or more cases and to types of DILI is
given in Fig. 2a. The most frequent DILI causes were
heparins, antibacterials and anticancer agents. Other
DILI causes were antimycotics, tuberculostatics and
antivirals. Pravastatin, ciclosporin and mesalazine
caused DILI in single cases only. Based on the number
of patients exposed, incidence rates were calculated and
are given in Fig. 2b. DILI incidence was highest for
anticancer agents (3.8%) followed by tuberculostatics
(2.4%). Incidence estimates for heparins, antibacterials,
antimycotics and antivirals were comparable and less
than 2%.
Incidence of DILI for heparins
In the study cohort, 675 patients were exposed to un-
fractionated heparin, 1576 to low-molecular-weight
heparins (mainly dalteparin) and 427 patients received
both types of heparin sequentially. Since 6 incident DILI
cases were attributed to unfractionated heparin and 20
to low-molecular-weight heparins, incidence estimates
were 0.9 (0.3, 1.9)% for unfractionated heparin and 1.3
(0.7, 2.0)% for low-molecular-weight heparins. The type
of liver injury was mostly hepatocellular (20 of 26,
Fig. 2a). Of the 19 patients with documented follow-up,
DILI was transient in 11 cases and recovered or im-
proved in 8 cases only after heparin was stopped. Thus,
heparin-associated DILI was mostly hepatocellular and
transient, and incidences were comparable for both
types of heparin.
Antibacterial-associated DILI
There were 19 incident DILI cases induced by antibac-
terials. Thorough care was taken in each case to exclude
increases of liver parameters caused by the treated
infection: in 3 cases, antibacterials were administered
prophylactically. In the 16 other cases, liver injury oc-
curred only after clinical and laboratory parameters
suggested recovery from infection. The type of liver in-
jury was hepatocellular in 9, mixed in 1 and cholestatic
in 9 cases (Fig. 2a). Eleven patients showed recovery, 5
patients exhibited improvement and 11 patients recov-
ered or improved only after antibacterials were stopped.
DILI was transient in 4 cases. Beta-lactams were in-
volved in 15 cases, sulphonamides in 2 and lincomycins
in 2. The beta-lactams causing DILI were amoxicillin/
clavulanic acid (9 cases), cephalosporins (4), ﬂoxacillin
(1) and imipenem (1). Based on 571 exposed patients,
DILI incidence in amoxicillin/clavulanic acid-treated
inpatients amounted to 1.6 (0.7, 3.0)%. Amoxicillin/
clavulanic acid-associated liver injury was cholestatic in
6 patients and hepatocellular in 3 (Table 3). However, in
all cases where c-glutamyl-transpeptidase was deter-
mined, it was elevated severalfold. The amoxicillin/cla-
vulanic acid-associated DILI cases exhibited a lower
median age of 44 (33, 69) years compared with a value of
69 (52, 81) years obtained for all amoxicillin/clavulanic
acid-exposed patients. Moreover, 42% of the amoxicil-
lin/clavulanic acid-associated DILI cases and 36% of the
exposed patients were female.
Anticancer agent-associated DILI
The causative agents in the seven incident anticancer
agent-associated DILI cases are given in Table 4. Except
for one cholestatic DILI caused by tretinoin, all other
cases showed hepatocellular DILI. Three patients
showed recovery and two patients exhibited improve-
ment. Antimetabolites were the cause of DILI in 4 cases,
Fig. 2 a Causative drugs in 57 incident cases of drug-induced liver
injury (DILI) according to drug class and types of liver injury. The
drugs most commonly causing DILI were heparins (ATC classiﬁ-
cation: B01AB), antibacterials for systemic use (J01), anticancer
agents (L01), antimycotics for systemic use (J02), tuberculostatics
(J04) and antivirals for systemic use (J05). b Incidence of drug-
induced liver for selected drug classes. Incidence rates were highest
for patients receiving anticancer agents (L01) and amounted to
3.8% (95% CI: 1.6, 7.4), followed by tuberculostatics with an
incidence of 2.4% (0.5, 7.0), antibacterials for systemic use with
1.5% (0.9, 2.2), heparins with 1.4% (0.9, 2.1), antimycotics with
1.1% (0.2, 3.3) and antivirals with 0.9% (0.1, 3.3). Values are given
as mean±95% CI
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alkaloids in 2, alkylating agent in 1 and tretinoin also in
1 case. The causality for the drug was probable in 4 and
possible in 3 cases. Among the latter, the concomitant
drug was another anticancer agent in 1 case. Thus, DILI
was mainly hepatocellular and concerned several anti-
cancer agents.
Exposure times before DILI
Figure 3 gives the exposure times for all incident cases
until DILI occurrence, i.e. the number of days elapsed
between the ﬁrst intake of the causative drug until DILI
occurred. Exposure times varied from just a few days to
over 2 weeks (10 cases). The hepatocellular type
outweighs the cholestatic type for short exposure times,
whereas for longer exposure times the partition into
hepatocellular and cholestatic type is more balanced.
Correspondingly, the median (Q1, Q3) exposure times
amounted to 4 (3, 6) days for hepatocellular and to 6 (4,
13) for cholestatic DILI cases.
Detection and evaluation of DILI by treating
physicians
In order to evaluate DILI detection by the physicians in
charge, the diagnoses and the text of the discharge letters
of all cases were examined (Table 5). DILI was diag-
Table 3 Incident cases with amoxicillin/clavulanic acid-induced liver injury
No. Sex Age
(years)
Time of
onset (days)
Typea Maximal values of Follow-upc
ALTb APb ASTb TBilib cGTb
1 Male 93 6 h 65.7 2.2 115 4.0 5.8 Improvement
2 Male 21 3 h 2.8 1.0 2.1 1.0 2.3 Improvement
3 Male 77 3 c 3.1 1.7 2.8 1.1 18.9 Recovery
4 Male 33 35 c 2.1 1.5 1.0 1.0 5.5 Recovery
5 Male 35 3 c 2.5 2.1 2.1 1.0 3.0 Improvement
6 Male 56 6 c 3.2 2.2 2.2 1.5 4.7 Censored
7 Male 48 4 c 4.4 4.4 1.9 3.5 – Improvement
8 Female 69 6 h 7.6 1.0 2.3 1.0 5.0 Improvement
9 Female 39 14 c 5.8 5.7 4.3 1.0 3.6 Improvement
a Type of liver injury: h corresponds to hepatocellular, c to chole-
static DILI
b Maximal elevations for alanine aminotransferase (ALT), alkaline
phosphatase (AP), aspartate amino-transferase (AST), total bili-
rubin (tBili) and c-glutamyl transpeptidase (cGT) in multiples of
the upper normal limits. Values below the upper limit are given as
1.0
c The term recovery implies that liver parameters did no longer fulﬁl
CIOMS criteria, whereas the term improvement was used for cases
where CIOMS criteria were still fulﬁlled, but liver parameters
started to decrease when patients left the cohort. The term censored
stays for patients leaving the cohort with liver parameters still
fulﬁlling CIOMS criteria and no improvement was documented
Table 4 Incident cases with liver injury induced by anticancer agents
No. Sex Age (years) Drug Time of onset (days) Typea Maximal values of Follow-upc
ALTb APb ASTb tBilib cGTb
Antimetabolites
1 Male 26 Cytarabined 2 h 4.4 1.0 2.2 1.3 1.5 tran/impr
2 Male 15 Mercaptopurine 7 h 2.3 1.0 1.0 – 1.0 censored
3 Female 20 Methotrexate 6 h 4.4 1.0 1.8 – – censored
4 Female 38 Methotrexate 4 h 3.6 1.0 1.0 – 1.0 recovery
Alkaloids
5 Male 26 Etoposided 2 h 4.4 1.0 2.2 1.3 1.5 tran/impr
6 Male 28 Vincristine 5 h 3.8 1.0 1.0 – 4.1 recovery
Alkylating agents
7 Male 60 Cyclo-phospamide 1 h 2.3 1.0 7.0 1.0 1.0 recovery
Miscellaneous
8 Male 65 Tretinoin 33 c 3.1 5.5 1.6 2.7 10.4 recovery
a Type of liver injury: h corresponds to hepatocellular, c to chole-
static according to the CIOMS criteria
b Maximal elevations for alanine aminotransferase (ALT), alkaline
phosphatase (AP), aspartate amino-transferase (AST), total bili-
rubin (tBili) and c-glutamyl transpeptidase (cGT) in multiples of
the upper normal limits. Values below the upper limit are given as
1.0
c The term recovery implies that liver parameters did no longer fulﬁl
CIOMS criteria, whereas the term improvement was used for cases
where CIOMS criteria was still fulﬁlled, but liver parameters starts
to decrease when patients left the cohort. The term censored stays
for patients leaving the cohort with liver parameters still fulﬁlling
CIOMS criteria and no improvement was documented. The term
tran/ impr was used for cases in which the parameters improved
despite of continuation of the oﬀended drug
d Numbers 1 and 5 correspond to the same patient. Based on the
presentation and the clinical course, both, cytarabine or etoposide
might have caused the liver injury
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nosed in only 23% of all incident cases and in 45% of
the prevalent cases. In addition, DILI was mentioned
somewhere else in the text in 9% and 3%, respectively.
Thus, a case detection procedure based on the recorded
diagnoses or the discharge letters would have missed 60–
70% of all cases. Even if we disregard the 34 missed,
mostly transient heparin-associated DILI cases, und-
erreporting still amounts to 40–60%. Interestingly, the
physicians in charge noted none of the 5 NSAID-asso-
ciated DILI cases. Thus, DILI is frequently missed or
not reported during routine care in medicine.
Discussion
In this study of medical inpatients, the DILI prevalence
at admission amounted to 0.7% and the overall inci-
dence during hospitalisation to 1.4%. Neither sex, age,
polymorbidity nor polypharmacy predisposed to DILI.
Heparins, antibacterials and anticancer drugs were most
frequently causative for DILI, whereas incidences were
highest for anticancer drugs and tuberculostatics. Of
patients identiﬁed by screening electronically for the
CIOMS laboratory criteria, 82% exhibited a disease-re-
lated liver injury and 18% a DILI. Furthermore, the
physicians in charge missed the majority of DILI diag-
noses for incident and prevalent cases.
DILI incidence in medical inpatients was estimated to
a value between 0.7% and 1.8% with a point estimate of
1.4%. The lower limit originates from the lower 95% CI
if the entire cohort was included, whereas the upper limit
corresponds to the upper 95% CI if the cohort was
limited to patients with liver parameter determinations.
Furthermore, 0.7% of patients were admitted with
DILI; thus, overall, 2.1% exhibited a DILI. This is be-
low the value of 3.7% [12] in a department of neurology
and is three times higher than the value of 0.7% ob-
tained by evaluating all liver parameter elevations
among 1964 consecutive hospitalisations [5]. Thus, DILI
occurs commonly in inpatients, especially in neurology
and medicine. The marked discrepancy to the low an-
nual incidences in outpatients of 0.014% [4] might arise
due to diﬀerent case detection methods, i.e. screening
laboratory results versus screening diagnoses or evalu-
ating physicians’ notiﬁcations, and/or be due to diﬀer-
ences in age, morbidity and drug exposures.
Among 489 patients, only 88 patients had DILI
resulting in a positive predictive value of 18% for a case
detection based on the CIOMS laboratory criteria. This
is in line with previous smaller studies in medicine
reporting positive predictive values of 12–17% [13, 14]
and slightly lower than the 31–37% for a department of
neurology [12]. These numbers indicate that automatic
signal generation would result in too many false-positive
alerts, at least if one uses the CIOMS criteria cut-oﬀ of
2 N. If the cut-oﬀ is increased to 2.5 N or 3 N, the po-
sitive predictive value increases only to 22% or 20%,
respectively. In turn, 28% or 49% of DILI cases would
be missed. In contrast, if we had relied on DILI detec-
tion by the physicians in charge, 52–68% of cases would
have been missed (Table 5). Thus, case detection for a
comprehensive DILI epidemiology study can neither be
accomplished only by laboratory screening nor by
analysing only patients’ records, but requires laboratory
data for screening combined with a thorough evaluation
of positive screenings by a specially trained physician or
pharmacist.
One might argue that the high number of DILIs
missed by the physicians in charge is not worrisome,
since none of the DILI cases developed severe or fatal
outcome and most cases did not show clinical symptoms
(data not shown). However, one-third of the 72 uncen-
sored patients only recovered after stopping the causing
drug, and in 10% other drugs were identiﬁed incorrectly
as causative for DILI. These numbers point towards the
importance of diagnosing all DILI cases as well as cor-
rectly identifying the causative drug(s) to be able to stop
the causative drugs and avoid unnecessary withdrawals
of essential medications.
Common DILI causes in our study were heparins,
antimicrobials, anticancer agents immunosuppressants,
statins and NSAIDs. Similar drugs were implicated in a
previous study at the Geneva University Hospital in
Switzerland [15]. Thus, these drugs seem to represent
Table 5 Detection and evaluation of drug-induced liver injury
(DILI) by the treating physicians
n Incident cases Prevalent cases
57 (100%) 31 (100%)
DILI diagnosed 13 (23%) 14 (45%)
DILI mentioned in
discharge letter
5 (9%) 1 (3.0%)
Causative drug correctly
identiﬁed
9 (16%) 9 (29%)
Wrong drug implicated 6 (10.5%) 3 (9.5%)
Causative drug not
speciﬁed
3 (5.0%) 3 (9.5%)
Fig. 3 Time of onset (days) of drug-induced liver injury (DILI) in
57 incident DILI cases. The time of onset was determined as the
number of days elapsed between the date at which the suspected
drug was started and the occurrence of liver injury
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indeed the most common DILI causes at larger hospitals
in Switzerland. Without exposure data, heparins and
antibacterials would be supposed to be the most frequent
DILI causes. However, if we also consider drug expo-
sures, DILI occurs almost twice as frequently with anti-
cancer agents and tuberculostatics as with antibacterials
and heparins. This nicely illustrates the importance of
exposure data for comparing risk rates among drugs.
Sex, age, polypharmacy and liver disorders are often
discussed as predisposing to DILI [14, 16, 17]. Since
patients with underlying liver disorders were excluded in
this study, we cannot evaluate the inﬂuence of liver
disease. Interestingly, we did not detect any diﬀerences
in sex, age, comorbidity and polypharmacy between
prevalent and incident DILI cases and the overall study
cohort. The observation that even for incident cases
polypharmacy was not increased suggests that it is
exposure to drugs with high hepatotoxic potential rather
than polypharmacy in general that predisposes to DILI.
These ﬁndings also suggest that predisposition to DILI
might rather depend on some pharmacogenetic trait
than on concomitant diseases, aging or hormones.
NSAIDs caused none of the incidents, but ﬁve of the
prevalent cases. An explanation might be that NSAIDs
were only sparsely used within the cohort (17%),
whereas acetaminophen (47%) and opioids (35%) were
more commonly administered. Interestingly, none of the
NSAID-associated prevalent cases was mentioned
among the discharge diagnoses or anywhere else in the
discharge letters, and all cases improved or recovered
only after stopping the NSAID. These ﬁndings suggest
that outpatient studies using case identiﬁcation by dis-
charge diagnoses might considerably underestimate
DILI incidences.
It is well established that heparins lead frequently to
asymptomatic aminotransferase elevations and DILI
usually transiently occurring after 5–10 days of treat-
ment [10]. All heparin-associated DILI cases in this
study corresponded closely to these characteristics. One
randomised controlled trial comparing unfractionated
heparin with low-molecular-weight heparin (fraxiparine)
reported a signiﬁcantly higher incidence of transaminase
elevations above 3 N for unfractionated heparin (3%)
than low-molecular-weight heparin (0.9%) [18]. Inci-
dence rates in our study were in the same range, but
showed no diﬀerences for low-molecular-weight and
unfractionated heparin. Thus, we cannot conﬁrm that
DILI is less common with low-molecular-weight hepa-
rins. Although heparin-induced DILI is usually asymp-
tomatic, a correct diagnosis can be essential for
preventing unnecessary withdrawals of essential drugs
incorrectly implicated as DILI causes.
Among the antibacterial-associated DILI cases,
amoxicillin/clavulanic acid was the most common cause
and led to DILI in 1.6% of exposed patients. In is well
known that clavulanic acid can lead to cholestatic liver
injury typically after 14 days of treatment [19, 20]. Also
in our study, DILI pattern was cholestatic in two-thirds
of the cases and exposures prior DILI varied between
3 days and 35 days. A recent review of all case reports
showed that 70% of the amoxicillin/clavulanic acid-
associated DILI cases were male and the average age
was 60 years [20]. In contrast, the median age for the
amoxicillin/clavulanic acid-associated cases in our study
was somewhat lower (44 years) than among amoxicol-
lin/clavulanic acid users (69 years). The fraction of fe-
male patients was not diﬀerent between amoxicillin/
clavulanic acid-associated DILI cases (36%) and
amoxicillin/clavulanic acid users (42%). Thus, our epi-
demiological analysis does not conﬁrm the predomi-
nance of older male patients for amoxicillin/clavulanic
acid-associated DILI in case series [20] suggesting that
the reported predominance might possibly be caused by
higher exposure rates in elderly males. Incidences of
amoxicillin/clavulanic acid-associated DILI in our
inpatient study were about 100 times higher than the
previously reported incidence rates in outpatients of
0.017%, i.e. 1.7 cases per 10,000 prescriptions [19]. Thus,
amoxicillin/clavulanic acid-associated DILI is mainly
cholestatic and occurs quite commonly in inpatients.
Anticancer agents are usually not mentioned among
drugs causing DILI. Nevertheless, in our study, we ob-
tained the highest incidence (3.8%) for anticancer
agents. Among seven cases, six were hepatocellular
suggesting that DILI with anticancer agents usually
exhibits a hepatocellular pattern with few exceptions,
such as for example tretinoin. The reason why antican-
cer agent-associated DILI is frequently overlooked
might be the severe underlying disease and the high
frequency and large variety of expected and tolerated
adverse drug eﬀects after chemotherapy.
In conclusion, our study demonstrates that in medical
inpatients DILI occurs in approximately one in 100
patients during hospitalisation, which is considerably
more common than reported for ambulatory care.
Incidences were highest for anticancer agents, tubercu-
lostatics, antibacterials and heparins. Since primary and
secondary disease-related liver injuries are also common
in this patient collective, screening laboratory results
according to the CIOMS laboratory criteria exhibits a
low speciﬁcity for DILI with a positive predictive value
of 18%. However, DILI is frequently missed by the
treating physician and therefore its detection by diag-
noses will result in misleadingly low incidence rates.
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